Anticancer Drug Sensitivity Testing, a Historical Review and Future Perspectives

Title:Anticancer Drug Sensitivity Testing, a Historical Review and Future Perspectives

Volume: 10 Issue: 1

Author(s): Da-Yong Lu*, Ting-Ren Lu, Jian Ding, Bin Xu, Jin-Yu Che and Hong-Ying Wu

Affiliation:

• ,0

Keywords: Anticancer drugs, cancer stem cell, clinical cancer therapy, drug combinations, drug sensitivity test, individualized cancer therapy, neoplasm metastasis.

Abstract: Background: Clinical cancer treatment and therapy have been gradually improved by experimental and clinical advancements worldwide, especially after the advent of different types of individualized cancer therapy (ICT).

Objective: Despite the longest history of anticancer drug sensitivity testing (DST) among ICT, its therapeutic applications for clinical cancer trials need to be updated.

Methods: DST techniques are widely diversified and improved a great deal, but they have not been matured to cure all cancer patients in clinics.

Results: The retrospection and panorama of historic and evolutionary developments of DST including clinical relevance, advantageous, technical cautions, limitations of varied models and methodologies at present stage are addressed.

Conclusion: Future directions and novel ideas must be established.

Cite this article as:

Lu Da-Yong*, Lu Ting-Ren, Ding Jian, Xu Bin, Che Jin-Yu and Wu Hong-Ying, Anticancer Drug Sensitivity Testing, a Historical Review and Future Perspectives, Current Drug Therapy 2015; 10 (1) . https://dx.doi.org/10.2174/157488551001150825100450